676361-01-6

Basic information

• Product Name: N₂-(3-chloro-4-methoxyphenyl)-N₄-cycloheptyl-6-(6-methyl-pyridin-2-ylmethoxy)-1,3,5-triazine-4,2-diamine
• Synonyms: N₂-(3-chloro-4-methoxyphenyl)-N₄-cycloheptyl-6-(6-methyl-pyridin-2-ylmethoxy)-1,3,5-triazine-4,2-diamine
• CAS NO: 676361-01-6
• Molecular Weight: 468.986
• Mol File: 676361-01-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N₂-(3-chloro-4-methoxyphenyl)-N₄-cycloheptyl-6-(6-methyl-pyridin-2-ylmethoxy)-1,3,5-triazine-4,2-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N₂-(3-chloro-4-methoxyphenyl)-N₄-cycloheptyl-6-(6-methyl-pyridin-2-ylmethoxy)-1,3,5-triazine-4,2-diamine(676361-01-6)
• EPA Substance Registry System: N₂-(3-chloro-4-methoxyphenyl)-N₄-cycloheptyl-6-(6-methyl-pyridin-2-ylmethoxy)-1,3,5-triazine-4,2-diamine(676361-01-6)

Safety Data

• Hazardous Substances Data: 676361-01-6(Hazardous Substances Data)

Upstream product

• 1122-71-0 2-(Hydroxymethyl)-6-methylpyridine 
• 502767-50-2 6-chloro-N₂-(3-chloro-4-methoxy-phenyl)-N₄-cycloheptyl-[1,3,5]triazine-2,4-diamine 

Relevant articles and documents

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.